Phase 1 Clinical Trial Data Indicate IGCÃ's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients - IGC Pharma, INC.

Press

Releases

December 2, 2021

Phase 1 Clinical Trial Data Indicate IGCÃ’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Related Posts

IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program

April 8, 2025

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

April 1, 2025

IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

March 26, 2025

CEO Update

Recap of AAIC24 Conference Participation and Poster Presentations

August 28, 2024

Desk of CEO Marijuana Reclass

July 25, 2024